Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4552W HIGH $3.54
Volume
19.34 M
Value Traded
1.25 M
Short % Float
13.3%
-60.56%Week
-66.58%1 Month
-75%3 Month
-75.07%6 Month
-88.1%5 Year
-88.1%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
51.59 M
EPS (TTM)
-0.96
P/E Ratio
-
Ent. Value
-62.23 M
Total Shares
107.21 M
Float Shares
97.56 M
Insiders
9.00%
Institutions
45.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CRBU Catalyst Timeline
Dated clinical, regulatory and corporate events for Caribou Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Caribou Biosciences, Inc.
229Total events
4Upcoming
34Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T2FDA Feedback Received
Subscribe to view catalyst details
Event history 50
▼Program Discontinuationvispa-celDiscontinuedCorporate
Caribou plans to discontinue vispa-cel allogeneic CAR-T program
relapsed or refractory B cell non-Hodgkin lymphomasource ↗
▼Program DiscontinuationCB-011DiscontinuedCorporate
Caribou plans to discontinue CB-011 allogeneic CAR-T program
relapsed or refractory multiple myelomasource ↗
●Management ChangeCorporate
Caribou Board of Directors approved initiating strategic alternatives process
▼Restructuring LayoffsCorporate
Caribou to implement substantial workforce reduction and cost reductions
●Quarterly UpdateCorporate
Caribou reports $113.8 million in cash, cash equivalents and marketable securities as of June 30, 2026
◆Oral Presentationvispa-celDiscontinuedPresentation
EHA 2026 oral presentation of long-term vispa-cel data in 2L LBCL
relapsed or refractory B cell non-Hodgkin lymphomasource ↗
▲Full Resultsvispa-celDiscontinuedClinical Data
Long-term efficacy and safety data from ANTLER phase 1 in 2L LBCL (data cutoff March 6, 2026)
second-line large B cell lymphomasource ↗
▲FDA Feedback Receivedvispa-celDiscontinuedFDA Meeting
FDA alignment on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL
second-line large B cell lymphomasource ↗
▲RMATCB-011DiscontinuedDesignation
FDA granted RMAT designation to CB-011
relapsed or refractory multiple myelomasource ↗
▲Oral PresentationCB-011DiscontinuedPresentation
Oral presentation at 2026 Tandem Meetings including clinical data disclosed in November 2025 and new supportive translational data
relapsed or refractory multiple myelomasource ↗
▲Poster Presentationvispacabtagene regedleucelPresentation
Poster presentation at 2026 Tandem Meetings including clinical data disclosed in November 2025 and new supportive translational data
relapsed or refractory B cell non-Hodgkin lymphomasource ↗
▲Enrollment MilestoneCB-011DiscontinuedTrial
Advancing CB-011 into dose expansion by end of 2025
relapsed or refractory multiple myelomasource ↗
◆FDA Feedback Receivedvispa-celDiscontinuedFDA Meeting
FDA recommended randomized controlled trial for vispa-cel pivotal phase 3
second-line large B cell lymphomasource ↗
◆Timing Guidancevispa-celDiscontinuedPresentation
Planned pivotal phase 3 trial design to be refined through continued FDA engagement in coming months
second-line large B cell lymphomasource ↗
▲Topline Readoutvispa-celDiscontinuedClinical Data
Positive data from ANTLER phase 1 trial for vispa-cel
relapsed or refractory B cell non-Hodgkin lymphomasource ↗
▲Topline ReadoutCB-011DiscontinuedClinical Data
Positive first clinical data from dose escalation of CaMMouflage phase 1 trial for CB-011
relapsed or refractory multiple myelomasource ↗
▲Full Resultsvispa-celDiscontinuedClinical Data
Positive data from ANTLER Phase 1 trial demonstrating efficacy and durability of vispa-cel on par with autologous CAR-T therapies
relapsed or refractory B cell non-Hodgkin lymphomasource ↗
●Oral Presentationvispa-celDiscontinuedPresentation
Conference call and webcast to discuss ANTLER trial data and pivotal Phase 3 trial design
relapsed or refractory B cell non-Hodgkin lymphomasource ↗
●Enrollment Updatevispa-celDiscontinuedTrial
Enrollment update: 84 patients enrolled in ANTLER trial as of September 2, 2025
relapsed or refractory B cell non-Hodgkin lymphomasource ↗
▼Enrollment Pausedvispa-celDiscontinuedTrial
Enrollment paused in cohort of third-line or later LBCL patients with prior CD19-targeted therapy
relapsed or refractory B cell non-Hodgkin lymphomasource ↗
▲Enrollment CompleteCB-010Trial
Completed enrollment of 20-patient confirmatory cohort in ANTLER trial
second-line large B cell lymphomasource ↗
▲Enrollment CompleteCB-011DiscontinuedTrial
Completed planned enrollment for dose escalation portion of CaMMouflage trial
relapsed or refractory multiple myelomasource ↗
▼Pipeline PrioritizationCorporate
Pipeline prioritization: discontinued CB-010 lupus trial, CB-012 AML trial, and preclinical research; workforce reduction ~32%
▼Trial DiscontinuedCB-010Trial
Discontinuation of GALLOP Phase 1 trial of CB-010 for lupus prior to first patient dosing
lupussource ↗
▼Trial DiscontinuedCB-012DiscontinuedTrial
Discontinuation of AMpLify Phase 1 trial of CB-012 for AML
relapsed or refractory acute myeloid leukemia (AML)source ↗
◆Trial InitiationCB-010Trial
Initiation of pivotal Phase 3 trial for CB-010 in 2L LBCL
second-line large B cell lymphomasource ↗
●Quarterly UpdateCorporate
Preliminary unaudited cash position of $212.5 million as of March 31, 2025
◆Oral PresentationPresentation
Corporate update at 43rd Annual J.P. Morgan Healthcare Conference
▲Trial InitiationCB-010Trial
Initiation of GALLOP Phase 1 trial for CB-010 in lupus
lupus nephritis and extrarenal lupussource ↗
▲Enrollment UpdateCB-012DiscontinuedTrial
Dose level 3 completed with no DLTs; enrolling at dose level 4
relapsed or refractory acute myeloid leukemiasource ↗
◆Topline ReadoutCB-010Clinical Data
Initial data from additional 2L LBCL cohort and CD19 relapsed cohort expected
second-line large B cell lymphomasource ↗
●Poster PresentationCB-010Presentation
Poster presentation on preclinical analysis of CB-010 for SLE at ACR Convergence 2024
refractory systemic lupus erythematosus (SLE)source ↗
Past FDA Catalysts and PDUFA Decisions
How CRBU actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | CB-011 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$35M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.3x
rNPV / MCap
Top 53%
Micro Cap(rank 349 of 658)
Percentile Rank
Caribou Biosciences, Inc. faces pipeline headwinds (35/100), with $540M risk-adjusted pipeline value, led by CB-011 in Relapsed/Refractory Multiple Myeloma (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CB-011 Monoclonal antibodyNCT05722418 | Relapsed/Refractory Multiple Myeloma | Phase 1 | RECRUITING | 50 | Dec 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every CRBU program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| vispa-cel Fast TrackRMATOrphan | second-line large B cell lymphoma | Phase 1 | 2026-06-12 | overall response rate: 82%; complete response rate: 67%; median progression free survival: 17.1 monthsRead More | Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 -- Single dose of vispa-cel produced durable responses in 2L LBCL patients 82% ORR, 67% CR rate, and 17.1-month mPFS -Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kelly Timothy POfficer (Chief Technology Officer) | Sell | -6,228 73,125 held | $1.93 | 02/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CRBU
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Kynam Capital Management, LP | 0.2 % (-33.3 %) | 4.41 M | 2.50 M |
CRBU Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CRBU ranks across every disease it competes in
Competitive Position is a premium feature
See how CRBU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCRBU News
CRBU▼ -45.6%on this news· ran to -58% by day 1
Caribou Biosciences to Evaluate Strategic Alternatives
Caribou Biosciences announced it will discontinue its allogeneic CAR-T cell therapy programs, vispa-cel and CB-011, due to challenges in securing necessary capital. The company is exploring strategic alternatives to maximize stockholder value, including potential mergers or acquisitions. This decision follows a significant reduction in workforce and clinical development activities.
Read more →CRBUCaribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Caribou Biosciences reported positive clinical data for its CAR-T therapies vispa-cel and CB-011 at the EHA 2026 Annual Meeting. Vispa-cel showed a strong overall response rate in patients with relapsed or refractory large B cell lymphoma, while CB-011 demonstrated durable responses in multiple myeloma patients. Despite a net loss, the company expects sufficient cash to fund operations through 2027.
Read more →CRBU▲ +5.4%on this news
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Caribou Biosciences, Inc. will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. CEO Rachel Haurwitz will lead a fireside chat on June 30, 2026. The event aims to enhance the company's visibility in the cell therapy sector, particularly regarding their CRISPR genome-editing technologies.
Read more →CRBUCaribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
Caribou Biosciences reported promising long-term data for vispa-cel, a CAR-T cell therapy for second-line large B cell lymphoma (LBCL), showing an 82% overall response rate and a 67% complete response rate. The therapy is designed to be an off-the-shelf solution for patients lacking curative treatment options. It holds promise due to its favorable safety profile and potential for outpatient administration. However, there are concerns following reports of serious adverse events, including deaths linked to the treatment.
Read more →CRBU▼ -7.3%on this newsshared move
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
Caribou Biosciences reported promising results for CB-011, an off-the-shelf CAR-T therapy, at the 2026 EHA Annual Meeting. The therapy showed a 92% overall response rate and 83% complete response rate in heavily pretreated patients with relapsed or refractory multiple myeloma. A case study highlighted a patient achieving a complete response after prior CAR-T therapy. The company plans to present further data in H2 2026.
Read more →CRBUCaribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Caribou Biosciences, Inc. will participate in the 2026 Jefferies Global Healthcare Conference. Rachel Haurwitz, the CEO, is scheduled for a fireside chat on June 4, 2026. This event will showcase Caribou's advancements in CRISPR genome-editing technologies and their focus on developing CAR-T cell therapies for hematologic malignancies.
Read more →CRBUCaribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
Caribou Biosciences, a clinical-stage CRISPR genome-editing company, will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The management team will engage in a fireside chat at the event, which will be accessible via webcast. Caribou is advancing its CAR-T cell therapies aimed at treating hematologic malignancies.
Read more →CRBUCaribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
Caribou Biosciences announced that two abstracts have been accepted for oral presentations at the 2026 EHA Annual Meeting. The presentations will cover the long-term efficacy of vispa-cel in treating relapsed or refractory B cell non-Hodgkin lymphoma and the ongoing evaluation of CB-011 for relapsed or refractory multiple myeloma. Both programs highlight innovative CAR-T cell therapies with significant regulatory support.
Read more →CRBUCaribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Caribou Biosciences reported its first quarter 2026 financial results and outlined progress in its clinical programs. The company achieved alignment with the FDA on the ANTLER-3 trial design for vispa-cel, an allogeneic CAR-T cell therapy for patients with relapsed or refractory large B cell lymphoma. Ongoing trials for CB-011 and updates on its clinical data are also anticipated in 2026. Financially, Caribou reported stable licensing revenue but noted a decrease in R&D expenses compared to the previous year.
Read more →CRBUCaribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
Caribou Biosciences, Inc. will have its CEO, Rachel Haurwitz, participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 13, 2026. The event will take place in Las Vegas, Nevada, and aims to enhance the company's visibility in the biopharmaceutical sector. Caribou is known for its CRISPR genome-editing technology and is developing therapies for hematologic malignancies.
Read more →CRBU▲ +10.5%on this news
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
Caribou Biosciences has received RMAT designation from the FDA for its allogeneic anti-BCMA CAR-T cell therapy, CB-011, aimed at treating relapsed or refractory multiple myeloma. This designation is based on promising initial clinical data, showing a 92% overall response rate and a 75% complete response rate in early trial participants. The ongoing CaMMouflage phase 1 clinical trial continues to evaluate the safety and efficacy of CB-011, with expected data updates in 2026. The designation aims to facilitate faster regulatory review to address unmet medical needs in this patient population.
Read more →CRBU▼ -5%on this news
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Caribou Biosciences reported its financial results for Q4 and full year 2025, highlighting a year of strong execution with advancements in its CAR-T cell therapy programs. The company showed positive phase 1 data for its allogeneic vispa-cel in LBCL and initiated dose expansion for CB-011 targeting multiple myeloma. Despite an increased revenue of $11.2 million from licensing collaborations, Caribou also faced challenges with a GAAP net loss of $148.1 million and recorded impairment charges. Ongoing engagement with the FDA for trial designs is set to facilitate further developments in 2026.
Read more →CRBUCaribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safet
Caribou Biosciences reported positive financial results and significant clinical data for Vispa-cel and CB-011 in their third quarter 2025 update. The ANTLER phase 1 trial for Vispa-cel showed promising efficacy results, indicating potential as a leading allogeneic CAR-T therapy for large B-cell lymphoma. Similarly, CB-011 demonstrated strong responses in patients with relapsed or refractory multiple myeloma. The company is advancing both therapies while having enough financial resources to continue their development.
Read more →CRBUCaribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
Caribou Biosciences announced favorable results from its ANTLER Phase 1 trial, indicating that its allogeneic CAR-T cell therapy, vispa-cel, shows comparable efficacy and durability to autologous CAR-T therapies in patients with relapsed or refractory large B cell lymphoma. With an overall response rate of 86% and a complete response rate of 63% in the optimized cohort, vispa-cel was also noted for its favorable safety profile, allowing for outpatient treatment. The company plans to move forward with regulatory discussions for a pivotal Phase 3 clinical trial to seek full approval.
Read more →CRBUCaribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update -- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash e
Caribou Biosciences has released its financial results for Q2 2025, showcasing a strong cash position of $184 million, sustaining operations into 2027. The company is focused on its CAR-T cell programs, CB-010 and CB-011, with promising data disclosures expected in H2 2025. Despite increasing net losses and a decrease in licensing revenue, encouraging Phase 1 results from both clinical trials reinforce the potential of these therapies.
Read more →CRBUCaribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
Caribou Biosciences reported its first-quarter 2025 financial results, revealing a net loss of $40 million and $212.5 million in cash reserves, projected to sustain operations until H2 2027. The company is focused on its lead clinical programs CB-010 and CB-011, both showing promising efficacy and aiming to release significant clinical dataset updates in the second half of 2025. Recent restructuring includes a workforce reduction and the discontinuation of non-core clinical trials, optimizing resources for its oncology therapies.
Read more →CRBUCaribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
Caribou Biosciences announced a strategic prioritization of its oncology pipeline, focusing on clinical programs CB-010 and CB-011. This decision involves workforce and cost reductions to extend its cash runway to H2 2027. As part of this strategic shift, the company will disclose robust clinical datasets for its lead programs in H2 2025, reinforcing its commitment to addressing unmet needs in oncology. The changes also entail discontinuation of trials outside of its primary focus areas, which may impact its pipeline diversity.
Read more →CRBUCaribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Caribou Biosciences has reported its financial results for Q4 and full year 2024, highlighting its ongoing clinical developments. The company plans to disclose two clinical data sets related to its CAR-T cell therapies in the first half of 2025. Despite a decrease in licensing revenue due to the termination of a collaboration with AbbVie, Caribou maintains a strong cash position that will fund its operations through 2026. Encouraging early results from clinical trials suggest potential improvements in patient outcomes.
Read more →CRBU▼ -5.5%on this news
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 -- CB-010 GALLOP Phase 1 trial initiated in lupus -- -- CB-012 AMpLify Phase 1 trial in r
Caribou Biosciences has initiated the GALLOP Phase 1 trial to evaluate its CAR-T cell therapy CB-010 in patients with lupus nephritis and extrarenal lupus. The company reported strong progress across its allogeneic CAR-T programs and outlined its clinical data expectations for 2025. With FDA Fast Track designations and a $281 million cash runway, Caribou is well-positioned to advance its key programs, including CB-010. The CEO expressed optimism about the potential impact of their therapies in the treatment landscape.
Read more →CRBU▲ +5.7%on this news· ran to +18% by day 3
Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer
Caribou Biosciences has appointed Sri Ryali as Chief Financial Officer, effective immediately. With over 20 years of finance and commercial experience in the biopharmaceutical industry, Mr. Ryali will oversee corporate finance, investor relations, and communications. His previous roles include CFO at Codexis and Eiger BioPharmaceuticals, bringing valuable expertise as Caribou plans to advance its clinical-stage programs in 2025 amidst ongoing developments in CRISPR genome editing technologies.
Read more →About Caribou Biosciences, Inc.
Headquarters2929 7TH STREET, SUITE 105, BERKELEY, CA, 94710
BIOPHARMAWATCH ELITE PLUS
Trade the next CRBU catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime